Hostname: page-component-cd9895bd7-p9bg8 Total loading time: 0 Render date: 2024-12-28T12:10:38.843Z Has data issue: false hasContentIssue false
  • English
  • Français

Quality of life in schizophrenia: Long-term follow-up in 362 chronic Spanish schizophrenic outpatients undergoing risperidone maintenance treatment

Published online by Cambridge University Press:  16 April 2020

J Bobes ,
M Gutiérrez ,
J Gibert ,
MP González ,
L Herraiz  and
A Fernández
J Bobes
Affiliation:
Department of Psychiatry, University of Oviedo, Julián Clavería 6, 33006Oviedo
M Gutiérrez
Affiliation:
Department of Psychiatry, H Santiago Apostol, Vitoria
J Gibert
Affiliation:
Department of Neurosciences, University of Cádiz
MP González
Affiliation:
Department of Psychiatry, University of Oviedo, Julián Clavería 6, 33006Oviedo
L Herraiz
Affiliation:
Janssen Research Foundation, Madrid, Spain
A Fernández
Affiliation:
Janssen Research Foundation, Madrid, Spain
Get access

Summary

Our aim was to determine the effect of risperidone monotherapy treatment on disability and on the quality of life of 318 schizophrenic outpatients who had been previously treated with other neuroleptics. Patients were assessed at baseline 2, 4 and 8 months using the BPRS, CGI, WHO/DDS and SF-36. BPRS scores showed a significant decrease at month 2, both in the total score and in each of the three clusters, negative, positive and depression/anxiety. WHO/DDS scores significantly decreased both in the overall score (from 51.8 to 37.4, P < 0.0001) and in the four dimensions. SF-36 scale scores and summary measures showed a significant improvement after 8 months of risperidone treatment. Risperidone long-term treatment (8 months) has a positive effect on clinical and on psychosocial outcomes. Females, paranoids patients and patients without history of use-abuse of substances showed greater improvements in quality of life.

Keywords

schizophrenic patientsrisperidone maintenance treatmentpsychosocial outcomesdisabilityquality of life
Type
Research Article
Information
European Psychiatry , Volume 13 , Issue 3 , May 1998 , pp. 158 - 163
Copyright
Copyright © Elsevier, Paris 1998

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

Alonso, J, Prieto, L, Anto, JMLa versión española del SF-36 Health Survey (Cuestionario de Salud SF-36): Un instrumento para la medida de los resultados clínicos Med Clin 1995; 104: 771–776Google Scholar
Aronson, SMCost-effectiveness and quality of life in psychosis: The pharmacoeconomics of Risperidone Clin Ther 1997; 19(1): 139–147CrossRefGoogle ScholarPubMed
Awad, AG, Voruganti, LNP, Heslegrave, RJA conceptual model of quality of life in schizophrenia: Description and preliminary clinical validation Qual Life Res 1997; 6: 21–26CrossRefGoogle ScholarPubMed
Barcia, D, Ayuso, JL, Herraiz, ML, Fernandez, AQuality of life of patients treated with Risperidone Ann Psiquiatr 1996; 12(6): 134–141Google Scholar
Bobes, J, Gonzalez, MPQuality of life in schizophreniaKatschnig, H, Freeman, H, Sartorious, NQuality of Life in Mental Disorders 1997 John Wiley and Sons Chichester165–178Google Scholar
Bobes, J, Gutierrez, M, Gibert, J, Gonzalez, MP, Herraiz, ML, Fernandez, AQuality of life in a large sample of schizophrenic outpatients undergoing Risperidone maintenance treatment American Psychiatric Association Annual Meeting N Res Program Abstr 1997 158Google Scholar
Browne, S, Roe, M, Lane, A, et al.Quality of life in schizophrenia: Relationship to sociodemographic factors, symptomatology and tardive diskinesia Acta Psychiatr Scand 1996; 94: 118–124CrossRefGoogle Scholar
Dernovsek, MZThe quality of life of schizophrenic outpatients ChichesterWPA Regional Meeting 1997CrossRefGoogle Scholar
Guy, WEarly Clinical Drug Evaluation (ECDEU) Assessment Manual for Psychopharmacology Publication No 76-338 GenevaNIH 1976Google Scholar
Heinrichs, DW, Hanlon, ET, Carpenter, WTThe Quality of Life Scale: An instrument for rating the schizophrenic deficit syndrome Schizophr Bull 1984; 10: 388–398CrossRefGoogle ScholarPubMed
Larsen, EB, Gerlach, JSubjective experience of treatment, side-effects, mental state and quality of life in schizophrenic outpatients treated with depot neuroleptics Acta Psychiatr Scand 1996; 93: 381–388CrossRefGoogle Scholar
Lehman, AFThe well-being of chronic mental patients. Assessing their quality of life Arch Gen Psychiatry 1983; 40: 369–373CrossRefGoogle Scholar
aLingjaerd, O, Ahlfors, UG, Bech, P, Dencker, SJ, Elgen, KThe UKU Side Effect Rating Scale Acta Psychiat Scand 1987 76 suppl 334 1–100CrossRefGoogle Scholar
Meltzer, HYDimensions of outcome with clozapine Br J Psychiatr 1992 160 suppl 17 46–53CrossRefGoogle Scholar
Meltzer, HY, Burnett, S, Bastani, B, Ramirez, LFEffects of six months of clozapine treatment on the quality of life of chronic schizophrenic patients Hosp Commun Psych 1990; 41: 892–897Google ScholarPubMed
Ministerio de Sanidad y Consumo Directrices para la realización de estudios de farmacovigilancia Circular No 18/90 de 21 de Noviembre de la Dirección General de Farmacia y Productos Sanitarios 1990 Ministerio de Sanidad y Consumo RockvilleGoogle Scholar
Naber, DSubjective effects of neuroleptic drugs. Relationships to compliance and quality of life Association of European Psychiatrists. 7th European Symposium Copenhage Eur Psychiatry 1994 9 suppl 1Google Scholar
Overall, JE, Gorham, DRIntroduction the Brief Psychiatric Rating Scale (BPRS): Recent developments in ascertainment and scaling Psychopharmacol Bull 1988; 24: 97–99Google Scholar
Skantze, K, Malm, U, Dencker, SJ, May, PHRQuality of life in schizophrenia Nord Psykiatr Tidsskr 1990 44 71–75CrossRefGoogle Scholar
Ware, JE, Sherbourne, CDThe MOS 36-item short-form health survey (SF-36): I. Conceptual framework and item selection Med Care 1992; 30: 473–483CrossRefGoogle ScholarPubMed
World Health Organization International Classification of Impairments, Disabilities and Handicaps. A manual of classification relating to the consequence of disease MadridWHO 1993Google Scholar
World Health Organization WHO Meeting on the Assessment of Quality of Life in Health Care (MNH/PSF/91.4) GenevaWHO 1991Google Scholar
Submit a response

Comments

No Comments have been published for this article.